Get started

Usstockmarket

Russell 2000 On verge of breakoutof a continuation inverse head & shoulders these projections are IMHO likely to be the final nail in the coffin for this massive bull run one of the complaints from Analysts is the lack of breath in the market well when the russell reaches these projections these analysts will likely claim victory and say see NOW we have a real bull market which is when you should be seeking shelter as when the last bears are bullish it means there is no one left to convince. And after 16 years from the 2009 bottom would be a fitting end to the secular bull With a Trump victory likely .. The Dems will in all likelihood prefer to leave him a big mess to clean up than a booming economy.
CME_MINI:RTY1!Long
by BallaJi
2
Election Volatility Shakes Up US MarketsS&P 500 ● The index retreated from its all-time high of 5,880, initiating a downward trend. ● A breakdown below the Rising Wedge pattern has been confirmed. ● Key support levels to watch: ➖ Immediate support: 5,670 ➖ Strong support: 5,400 Nasdaq Composite ● The index has hit an all-time high near the 18,750 level before beginning to retreat. ● After breaking through the trendline support, the index is currently hovering slightly above the next immediate support level. ● If it dips below this support, we could see a significant drop, potentially driving the index down to the 16,670 level. **This market volatility is consistent with historical trends during US presidential election years. The 2024 election is particularly unpredictable due to conflicting economic indicators and potential delays in results.
SP:SPXShort
by NaranjCapital
Why Zaza bought Nokia shares at $4.00 and is holding now30 Oct, Bota Kiri, Perak Darul Ridzuan: Why Nokia Stock Could Be Your Best Choice Right Now 📈 If you're looking for a stock with potential to grow, now might be the right time to consider Nokia (NYSE: NOK). Priced around $4.00, Nokia stock offers an attractive long-term investment opportunity. 🌟 Why Zaza & Team, ZZCM Bought Nokia at $4.00 Zaza recently purchased Nokia shares at $4.00, confident that the company has promising future projects to drive growth. Here’s why Zaza feels optimistic about the future of this tech company. Exciting Projects in 5G & Future Technologies 🚀 Nokia is strengthening its position in the 5G industry, which is increasingly important worldwide. Nokia’s 5G infrastructure and network solutions are recognized as solid. With partnerships with several major telecom operators, Nokia is now a leading provider of 5G technology in multiple countries. Beyond 5G, Nokia is also focusing on new technologies like 6G, AI networking, and the Internet of Things (IoT). These projects open new revenue streams for Nokia and position it for substantial gains when these technologies are adopted more widely. Positive Recent Developments for Nokia 📊 Recent developments have helped solidify Nokia's prospects: 👉 Partnerships with Major Telecom Companies: Nokia has numerous agreements with prominent telecom companies in Europe, North America, and Asia 🌍. These deals not only bring stable revenue but also reinforce Nokia’s brand in the market. 👉 Government Support & Strategic Contracts: Nokia recently secured contracts for secure communication networks with government agencies in several countries. This further proves Nokia is a trusted partner for secure networks 💼. 👉 Investment in Cloud & Edge Computing: Nokia is focusing on cloud and edge computing, increasingly vital for digital transformation 🔗. Nokia can offer end-to-end solutions from 5G to cloud services. Benefits of Buying Nokia Now Attractive Valuation: With a price around $4.00, Nokia is considered undervalued. Strong Financials: Nokia has a solid balance sheet, enabling continued investment in new technology. Dividend Potential: As Nokia’s financial position strengthens, there’s potential for increased dividends, which would be attractive to shareholders. Continued Demand: With growing digitalization, demand for 5G, cloud, and IoT is expected to keep rising 📈. So, Why Now is the Best Time to Buy 💰 With a low price and bright prospects, Zaza believes Nokia is well-positioned for growth. With its focus on 5G, IoT, AI, and edge computing, Nokia could be a profitable long-term investment opportunity. Buying now at around $4.00 offers you the chance to get in early before these projects make a full impact. 🚀
NYSE:NOKLong
by Zezu_Zaza
UNLOCK PROFITS! 5 Opportunities to Capitalise1. Tesla (Weekly Timeframe) NASDAQ:TSLA ● A symmetrical triangle pattern is clearly visible on the weekly chart. ● Following a recent breakout with strong volume, the price is likely to rise significantly. 2. Lam Research Corporation (Weekly Timeframe) NASDAQ:LRCX ● After breaking out of the cup and handle pattern, the price surged to an all-time high around the 113 level. ● A notable rejection from this peak caused a pullback to the previous breakout level. ● The price is currently consolidating at this level, preparing for a potential upward move. 3. Tapestry (Daily Timeframe) NYSE:TPR ● The stock has been trading within a rectangle pattern for a while. ● Now, following a robust breakout supported by significant volume, the stock price is primed for an upward trajectory. 4. Oppenheimer Holdings (Daily Timeframe) NYSE:OPY ● After breaking out of a bullish pennant pattern, the stock price is targeting higher levels. ● The breakout was accompanied by significantly high trading volume. 5. Deckers Outdoor Corporation (Daily Timeframe) NYSE:DECK ● The stock price has formed a symmetrical triangle pattern. ● A recent breakout could drive the price to higher levels.
NASDAQ:TSLALong
by NaranjCapital
Abbott Labs Shakes Off Downtrend, Sets Sights on $142 milestoneIn December 2021, the stock price hit an all-time high near the 142 mark, after which it experienced a significant drop. Following this decline, the price found support around the 90 level and began to recover. Last week, the stock managed to break through the upper boundary of the descending parallel channel, setting the stage for additional upward momentum. An immediate resistance level is noted at the 122 level, and a substantial movement is expected if this level is surpassed.
NYSE:ABTLong
by NaranjCapital
The Payment Card Titan: Comparing Visa, Mastercard, and Amex◉ Abstract The global credit card market is projected to grow from USD 559.18 billion in 2023 to USD 1,146.62 billion by 2033, driven by advancements in digital payment technologies, e-commerce growth, increased financial literacy, and urbanization, especially in Asia-Pacific. Visa leads the market with a 38.73% share, followed by Mastercard and American Express. Visa and Mastercard operate primarily as payment networks, while American Express both issues cards and offers unique rewards. Financially, all three companies show strong revenue growth, with American Express yielding the highest ROI but also carrying significant debt. Despite this debt, American Express appears undervalued based on financial ratios. Overall, while American Express presents an attractive investment opportunity, Visa and Mastercard also demonstrate solid fundamentals and growth potential for investors in the expanding credit card market. Read the full analysis here . . . ◉ Introduction The Global Credit Card Market Size was Valued at USD 559.18 Billion in 2023 and the Worldwide Credit Card Market Size is Expected to Reach USD 1146.62 Billion by 2033, ◉ Key Growth Drivers ● Digitalization and Technology: Advancements in payment technologies, including mobile wallets and contactless payments, enhance convenience and security. ● E-Commerce Growth: The rise of online shopping increases demand for credit card payments, as consumers prefer their ease and safety. ● Financial Literacy: Improved understanding of financial products encourages more consumers, especially in developing regions, to adopt credit cards. ● Urbanization: Growing urban populations, particularly in Asia-Pacific, lead to greater access to banking services and credit facilities. ● Emerging Markets: Rising disposable incomes in developing countries drive new credit card accounts as financial institutions expand their offerings. ● Consumer Convenience: The preference for quick and easy payment methods boosts credit card usage over cash transactions. ● Rewards Programs: Attractive loyalty programs incentivize consumers to use credit cards for everyday purchases. ● Regulatory Support: Government initiatives promoting cashless transactions foster a favourable environment for credit card adoption. ◉ Market Overview As of 2022, the global credit card market was primarily led by Visa, which held a 38.73% share of the worldwide payment volume. Mastercard followed with a 24% market share, while American Express (Amex) accounted for 4.61%. Notably, China UnionPay is also a major player in this space, surpassing Amex in terms of purchase volume ◉ Key Players in the Payment Card Industry 1. Visa NYSE:V ● Market Cap: $552 B ● Market Share: 38.73% ● Business Model: Payment network facilitating transactions between consumers, businesses, banks, and governments globally. ● Card Issuance: Does not issue cards itself. ● Global Reach: Extensive acceptance network across more than 200 countries. 2. Mastercard NYSE:MA ● Market Cap: $474 B ● Market Share: 24% ● Business Model: Payment processor and network partnering with banks to offer various card products. ● Card Issuance: Does not issue cards itself. ● Global Reach: Broad acceptance worldwide with diverse products catering to different consumer needs. 3. American Express NYSE:AXP ● Market Cap: $203 B ● Market Share: 4.61% ● Business Model: Card issuer and payment network offering unique benefits and rewards directly to cardholders. ● Card Issuance: Issues its own cards. ● Global Reach: High acceptance rate in the US (99% of merchants), lower in Europe and Asia due to higher transaction fees. ◉ Technical Aspects ● From a technical perspective, there's a notable similarity among the three stocks: each is exhibiting strong bullish momentum, consistently achieving higher highs and higher lows. ● All three stocks have formed a Rounding Bottom pattern, and after breaking out, their prices have climbed to new heights. ● While Mastercard and American Express are currently trading at their all-time highs, Visa is positioned just below its peak. ◉ Relative Strength The chart vividly demonstrates that American Express has excelled remarkably, achieving a return of nearly 85%, whereas Mastercard and Visa have delivered returns of 28% and 20%, respectively. ◉ Revenue & Profit Analysis 1. Visa ● Year-over-Year ➖ In FY23, Visa achieved a remarkable revenue increase of 11.4%, reaching $32.7 billion, up from $29.3 billion in FY22. ➖ The EBITDA for FY23 also saw a significant rise, totalling $22.9 billion compared to $20.6 billion in FY22. ● Quarter-over-Quarter ➖ In the latest June quarter, Visa's revenue rose to $8.9 billion, slightly surpassing the $8.8 billion reported in March 2024. This reflects a year-over-year growth of nearly 9.5% from $8.1 billion in the same quarter last year. ➖ The EBITDA for the most recent June quarter reached $6.2 billion, indicating an almost 9% increase from $5.7 billion in the same quarter last year. ➖ In June, the diluted EPS saw a modest rise, climbing to $9.35 (LTM) from $8.94 (LTM) in March 2024, which represents a notable year-over-year increase of 18.6% from $30.3 (LTM). 2. Mastercard ● Year-over-Year ➖ Mastercard's revenue for FY23 experienced a robust growth of 12.9%, reaching $25.1 billion, up from $22.2 billion in FY22. ➖ The EBITDA for FY23 also increased, reporting $22.9 billion, up from $20.6 billion in FY22. ● Quarter-over-Quarter ➖ In the recent June quarter, Mastercard's revenue climbed to $7.0 billion, compared to $6.3 billion in March 2024. Year-over-year, this marks an increase of nearly 11% from $6.3 billion in the same quarter last year. ➖ The EBITDA for the latest June quarter was $4.4 billion, reflecting an almost 9% rise from $3.9 billion in March 2024. ➖ In June, the diluted EPS saw a slight increase, rising to $13.08 (LTM) from $12.59 (LTM) in March 2024, which is a significant year-over-year increase of 23% from $10.67 (LTM). 3. American Express ● Year-over-Year ➖ For the fiscal year 2023, the company experienced a remarkable revenue growth of 9.7%, reaching an impressive $55.6 billion, compared to $50.7 billion in fiscal year 2022. ➖ Additionally, operating income showed a positive trajectory, with fiscal year 2023 reporting $10.8 billion, an increase from $10 billion in the previous fiscal year. ● Quarter-over-Quarter ➖ In the latest June quarter, revenue continued its upward trend, totalling $15.1 billion, up from $14.5 billion in March 2024. This represents a significant year-over-year growth of nearly 8.7% from $13.9 billion in the June quarter of the previous year. ➖ Furthermore, operating income for the June quarter reached $3.2 billion, marking a substantial increase of almost 19% from $2.7 billion in the same quarter last year. ➖ The diluted earnings per share (EPS) also saw a remarkable rise in June, climbing to $13.39 (LTM) from $12.14 (LTM) in March 2024, which is a significant jump of 36% compared to $9.83 (LTM) in the same quarter last year. ◉ Valuation ● P/E Ratio ➖ Visa stands at a P/E ratio of 29.1x. ➖ Mastercard is at a P/E ratio of 38.7x. ➖ American Express shows a P/E ratio of 20.6x. ➖ When we analyze these figures, it becomes clear that American Express appears significantly undervalued compared to its peers. ● P/B Ratio ➖ Visa has a P/B ratio of 14.3x. ➖ Mastercard's P/B ratio is a staggering 64x. ➖ American Express, however, has a P/B ratio of just 6.8x. This further reinforces the notion that American Express is currently undervalued in the market. ● PEG Ratio ➖ Visa's PEG ratio is 1.56. ➖ Mastercard's PEG stands at 1.71. ➖ American Express shines with a PEG ratio of just 0.56. ➖ This metric also highlights American Express's superior value proposition compared to its peers. ◉ Cash Flow Analysis ➖ Visa's operating cash flow for the fiscal year 2023 has risen to $20.8 billion, marking a notable increase from $18.8 billion in fiscal year 2022. ➖ Similarly, Mastercard has experienced growth in its operating cash flow, which has reached $12 billion in fiscal year 2023, up from $11.2 billion in the previous year. ➖ In contrast, American Express has reported a significant decline in its operating cash flow, decreasing from $21.1 billion in fiscal year 2022 to $18.6 billion in fiscal year 2023. ◉ Debt Analysis 1. Visa ● Debt to Equity Ratio: Approximately 0.52 as of June 2024, indicating a stable financial structure with moderate leverage. ● Total Debt: About $20.6 billion. ● Total Shareholder Equity: $39.7 billion. ● Analysis: Visa's ratio reflects a cautious debt approach, balancing equity and debt financing, with net debt well-supported by operating cash flow, enhancing financial stability. 2. Mastercard ● Debt to Equity Ratio: Approximately 2.10, indicating a higher reliance on debt compared to Visa 5. ● Total Debt: $15.6 billion. ● Total Shareholder Equity: $7.5 billion. ● Analysis: Mastercard’s higher ratio suggests it is more aggressive in leveraging debt for growth initiatives compared to Visa. This strategy may lead to greater volatility in earnings due to interest obligations. 3. American Express ● Debt to Equity Ratio: Approximately 1.80, indicating a significant level of debt relative to equity 5. ● Total Debt: $53.2 billion. ● Total Shareholder Equity: $29.54 billion. ● Analysis: American Express’s ratio shows a strong reliance on debt financing, which can enhance growth but also introduces risks related to interest payments and market conditions. ◉ Top Shareholders 1. Visa ● The Vanguard Group has notably boosted its investment in Visa, now commanding a remarkable 7.52% share, reflecting a 0.62% increase since the close of the March quarter. ● In contrast, Blackrock maintains a stake of approximately 6.7% in the firm. 2. Mastercard ● When it comes to Mastercard, Vanguard has also made strides, raising its ownership to an impressive 8.27%, which is a 1.02% uptick since the end of March. ● Blackrock, on the other hand, has a substantial 7.56% stake, showing a 1.17% growth from the same period. 3. American Express ● As for American Express, Warren Buffet’s Berkshire Hathaway boasts a significant 21.3% stake in the company. ● Meanwhile, Vanguard holds a 6.36% interest, while Blackrock has a 5.89% share. ◉ Conclusion After a thorough analysis of both technical and financial indicators, we find that American Express offers a compelling valuation opportunity that is likely to attract investors. Nonetheless, it is important to recognize the significant debt load the company carries, a concern that also extends to Mastercard. ● From a technical standpoint, the chart for American Express seems to be stretched thin. Investors might want to hold off for a corrective dip to secure a more advantageous entry point. ● Mastercard's financial results reflect solid performance, though it carries a high level of debt. The technical chart indicates a slight overvaluation. Savvy investors might look to build their positions during times of price stabilization. ● Visa presents a well-rounded synergy between its technical and fundamental metrics. Its chart reveals a remarkable rebound, approaching previous all-time highs after a notable decline. The company's valuation and growth potential make it a compelling investment choice.
Editors' picks
NYSE:VLong
by NaranjCapital
7
Globus Medical: Approaching resistance, is a breakthrough comingWeekly Chart ● The stock has tested the trendline resistance multiple times. ● Currently, it is trading just below this level. ● A breakout above this resistance is anticipated in the near future. ● Following the breakout, the price may increase. Daily Chart ● A Symmetrical Triangle pattern has formed. ● A strong breakout has taken place, supported by significant volume. ● The price is now set for a potential upward movement.
NYSE:GMEDLong
by NaranjCapital
S&P Pharmaceutical Sector: A Prescription for Growth● The S&P Pharmaceutical sector has great potential for growth. ● The weekly chart shows that after breaking out of the Symmetrical Triangle Pattern, the ETF had a short period of consolidation and is now ready for a rise. ● The daily chart also indicates a Cup & Handle Pattern, with the price trending upward post-breakout. As the industry revives, certain stocks are ready to achieve similar success Key stocks to watch: Hims & Hers NYSE:HIMS ● The price has broken the trendline resistance with high volume. ● More upward movement is likely to follow. Crinetics Pharmaceuticals NASDAQ:CRNX ● Mirrors HIMS' chart pattern. ● Poised for robust growth after breakout.
AMEX:XPHLong
by NaranjCapital
POET: A Technical Play with Fundamental RisksThe recent announcement of POET Technologies, Inc.'s ( NASDAQ:POET ) collaboration with Mitsubishi Electric on September 19, 2024, suggests greater upside potential for the company. Given the current trend, the stock could reach $6-7 per share by year-end. Over the past year, the stock has risen 56%, with a 377% increase year-to-date. Despite this strong performance, there are several risks to consider: • Negative net income (the company has not been profitable) • Frequent stock-based compensation (a 39% increase in shares outstanding since 2020) • Negative operating cash flow • Regulatory risks related to business operations in China While there is potential for substantial price growth, it does come with risks. I think starting with a small position and monitoring the technical and fundamental developments is the best way to play this opportunity.
NASDAQ:POETLong
by PeakInvestmentStrategies
Exxon's Make-or-Break Moment: $123 Resistance in FocusThe chart distinctly illustrates that the stock has been in a consolidation phase for over a year and is presently trading slightly below its resistance zone. For a potential upward movement, the price must surpass the 123 level and maintain its position above this threshold. At the same time, there is a significant likelihood that the stock price may encounter rejection once more, leading to a decline towards its trendline support level.
NYSE:XOM
by NaranjCapital
1
Ralph Lauren: Elevate Your Wealth with the Essence of Luxury◉ Abstract Ralph Lauren is thriving in the booming luxury apparel market. The company, founded in 1967, has a market cap of $11.83 billion and generates nearly 44% of its revenue from North America, totaling $2.93 billion. The industry is valued at approximately $110.13 billion in 2024 and projected to reach $151.32 billion by 2029, growing at a CAGR of 6.56%. Recent technical analysis shows Ralph Lauren's stock has outperformed the NYSE Composite index with a 66% annual return. Despite a slight revenue increase of 2.9% year-on-year, EBITDA soared to $1,024 million, reflecting strong financial health. With a current P/E ratio of 17.4x, Ralph Lauren presents an attractive investment opportunity amidst rising global wealth and consumer demand for luxury goods. Read full analysis here . . . ◉ Introduction The global luxury apparel market is currently experiencing significant growth, driven by various factors including increasing disposable incomes, brand loyalty, and the rising influence of social media on consumer behaviour. Here’s a detailed overview of the market size and growth outlook: ◉ Current Market Size According to Mordor Intelligence, the global luxury apparel market was valued at approximately USD 110.13 billion in 2024, with expectations to grow to USD 151.32 billion by 2029, reflecting a CAGR of 6.56%. ◉ Growth Drivers ● Increasing Wealth: The rising number of millionaires globally and growing middle-class affluence, particularly in regions like Asia-Pacific, are significant contributors to luxury apparel demand. ● Consumer Trends: There is a growing perception that luxury goods enhance social status, which fuels consumer interest in high-end fashion. ● Digital Influence: Enhanced online shopping experiences and the effective use of social media for marketing have opened new avenues for luxury brands to reach consumers. ◉ Regional Insights ● Europe Dominant Market: Holds a market share of approximately 34% to 43%. The presence of numerous luxury brands and high purchasing power among consumers drive demand, supported by significant tourist spending on luxury goods. ● North America Strong Demand: The U.S. is a key player, characterized by a wealthy consumer base and increasing brand loyalty, particularly among younger generations who view luxury items as status symbols. ● Asia-Pacific Fastest Growing Market: Anticipated to grow rapidly due to rising disposable incomes and brand awareness, especially in countries like China and India. ● Latin America Emerging Potential: Currently holds a smaller market share but shows promise for growth as consumer awareness and travel increase. ● Middle East & Africa Limited Contribution: This region contributes the least to the luxury apparel market, although countries like the UAE are seeing growth due to tourism. The overall outlook for the luxury apparel market remains optimistic, supported by evolving consumer preferences and increasing global wealth. Amidst the global luxury apparel market's promising growth prospects, we have identified Ralph Lauren as a prime opportunity for investment. With its robust financial performance and impressive technical indicators, Ralph Lauren is well-positioned to propel success. ◉ Company Overview Ralph Lauren Corporation NYSE:RL is a renowned American fashion company known for its high-quality, luxury lifestyle products. Founded in 1967 by the iconic designer Ralph Lauren, the company has become a global symbol of timeless style and sophistication. The company offers a wide range of products, including apparel, footwear, accessories, home goods, fragrances, and hospitality. Ralph Lauren's iconic polo shirt and strong brand identity have contributed to its success, making it a global leader in the luxury fashion industry. ◉ Investment Advice 💡 Buy Ralph Lauren Corporation NYSE:RL ● Buy Range - 190 - 193 ● Sell Target - 245 - 250 ● Potential Return - 27% - 30% ● Approx Holding Period - 8-10 months ◉ Market Capitalization - $11.83 B ◉ Peer Companies ● Tapestry NYSE:TPR - $10.59 B ● Levi Strauss NYSE:LEVI - $8.57 B ● PVH Corp. NYSE:PVH - $5.44 B ● Columbia Sportswear Company NASDAQ:COLM - $4.87 B ◉ Relative Strength The chart clearly illustrates that Ralph Lauren has greatly outperformed the NYSE Composite index, achieving an impressive annual return of 66%. ◉ Technical Aspects ● Monthly Chart ➖ The monthly chart clearly shows that the stock price faced several rejections near the 190 level, which ultimately triggered a significant drop, brought the price down to the 66 level. ➖ Afterward, the price experienced various fluctuations and, after a prolonged consolidation phase, developed an Inverted Head & Shoulders pattern. ➖ Upon breaking out, the price surged upward but encountered resistance again at the previous resistance zone. ➖ However, after a pullback, the stock has successfully surpassed this resistance for the first time in almost 11 years. ● Daily Chart ➖ On the daily chart, the price has formed a Rectangle pattern following a brief consolidation phase and has recently made a breakout. ➖ If the price can hold above the 190 level, we can expect a bullish movement in the coming days. ◉ Revenue Breakdown - Location Wise Ralph Lauren Corporation is a global luxury brand with a strong presence in various regions. ➖ North America remains Ralph Lauren's biggest market, contributing nearly 44% of its total revenue, which amounts to $2.93 billion. ➖ In Europe , the brand is seeing consistent growth, with revenue reaching around $2 billion, making up about 30% of total earnings. ➖ Asia , especially China, is becoming a key player for Ralph Lauren, generating approximately $1.58 billion, or 24% of total revenue. ◉ Revenue & Profit Analysis ● Year-on-year ➖ In the fiscal year 2024, the company achieved a modest revenue increase of 2.9%, totaling $6,631 million, compared to $6,443 million in the prior year. ➖ On the other hand, EBITDA growth has been remarkable, soaring to $1,024 million from $801 million in FY23. The current EBITDA margin stands at an impressive 15.5%. ➖ Additionally, diluted earnings per share (EPS) experienced a substantial year-over-year rise of 28%, reaching $9.71 in FY24, up from $7.58 in FY22. ● Quarter-on-quarter ➖ In terms of quarterly performance, the company reported a decline in sales over the last three quarters, with the most recent quarter showing sales of $1,512 million, down from $1,568 million in March 2024 and $1,934 million in December 2023. ➖ Nevertheless, EBITDA demonstrated significant growth in the June quarter, climbing to $265 million from $176 million in March 2023. ◉ Valuation ● P/E Ratio ➖ Current P/E Ratio vs. Median P/E Ratio The current price-to-earnings ratio for this stock stands at 17.4x, which is notably elevated compared to its four-year median P/E ratio of 5.7x. This suggests that the stock is presently overvalued. ➖ Current P/E vs. Peer Average P/E When evaluating the stock's Price-To-Earnings Ratio of 17.4x, it shows a more attractive valuation, as it is lower than the peer average of 25.5x. ➖ Current P/E vs. Industry Average P/E RL is positioned at a more appealing price point, with a Price-To-Earnings Ratio of 17.4x, which is significantly less than the US Luxury industry's average of 19.x. ● P/B Ratio ➖ Current P/B vs. Peer Average P/B The current P/B ratio reveals that the stock is considerably higher than its peers, with a ratio of 5x compared to the peer average of 3x. ➖ Current P/B vs. Industry Average P/B In comparison to the industry average, RL's current P/B ratio of 5x indicates that it is substantially overvalued, as the industry average is only 2.2x. ● PEG Ratio A PEG ratio of 0.54 suggests that the stock is undervalued relative to its expected earnings growth. ◉ Cash Flow Analysis In fiscal year 2024, operational cash flow experienced remarkable growth, reaching $1,069 million, a substantial increase from $411 million in fiscal year 2023. ◉ Debt Analysis The company currently holds a long term debt of $1,141 million with a total equity of $2,367 million, makes long-term debt to equity of 48%. ◉ Top Shareholders ➖ The Vanguard Group has significantly increased its investment in this stock, now owning an impressive 8.23% stake, which marks a 3.9% rise since the end of the March quarter. ➖ Meanwhile, Blackrock holds a stake of around 4.11% in the company. ◉ Conclusion After a thorough evaluation, we find that Ralph Lauren Corporation is strategically poised to thrive in the expanding luxury apparel market, driven by increasing disposable incomes and a growing appetite for high-end products.
NYSE:RLLong
by NaranjCapital
Coca-Cola's Bull Run Intensifies: Pole & Flag Breakout Expected!The chart shows that the stock price encountered resistance near the $65 level, subsequently dropping to $52, where it found support. After rebounding from this support, the price began to rise, successfully breaking through the Inverted Head & Shoulders pattern that had formed during the consolidation phase. Following this breakout, the price entered another consolidation period, created an Ascending Triangle Pattern. With another breakout, the stock price surged to an all-time high of $73.5 before experiencing a pullback. A bullish Pole & Flag pattern has emerged on the chart, signaling a potential continuation of the upward trend. It is expected that the price will break through this pattern and reach new highs in the near future.
NYSE:KOLong
by NaranjCapital
2
Corcept Therapeutics: A Shining Star in US BiotechCorcept Therapeutics is making waves in the booming U.S. biotech scene, with its stock surging 46.2% over the past six months. The company, known for its Cushing's syndrome drug, Korlym, reported a staggering 39.1% year-over-year sales increase, reaching $310.6 million in H1 2024. With a market cap of $4.42 billion, Corcept is actively developing new treatments like Relacorilant, which shows promise in clinical trials. Despite a high PE ratio of 35.3x compared to the industry average of 19x, its strong revenue growth and commitment to R&D position it as a solid investment opportunity in the fast-growing biotech market projected to reach $1,786 billion by 2033. ◉ The US Biotech Industry Outlook The biotech boom in the U.S. is hotter than a California summer! Fueled by groundbreaking tech and government cheerleading, the industry is soaring higher than a SpaceX rocket. According to Vision Research Reports, the market is projected to soar by 12.4% CAGR from 2024 to 2033. This rapid expansion is driven by advancements in areas like genomics, gene editing, and personalized medicine, positioning the U.S. as a global leader in healthcare innovation. ➖ The US biotechnology market size was valued at $552.43 billion in 2023 and is anticipated to hit around $1,786 billion by 2033. ➖ Key players like Abbvie Inc., Genentech Inc., and Amgen Inc. are leading the market. Acknowledging the remarkable expansion of the biotech sector, we are taking a closer look at a stock that is showing considerable strength in its technical chart, complemented by robust financial performance. ◉ Company Overview Corcept Therapeutics NASDAQ:CORT is a biopharmaceutical company dedicated to developing innovative treatments for severe endocrine, oncologic, and metabolic disorders. Their lead product, Korlym, is approved for Cushing's syndrome, a rare endocrine condition. Corcept is also advancing several pipeline candidates, including relacorilant for Cushing's syndrome, treatments for various cancers, and potential therapies for neurological conditions like amyotrophic lateral sclerosis and nonalcoholic steatohepatitis. Founded in 1998, Corcept is based in Menlo Park, California. ◉ Significant Stock Performance of Corcept Therapeutics Corcept Therapeutics Incorporated's stock price has risen 46.2% in the past six months, despite a 2% industry decline. This surge is attributed to strong demand for Korlym, the company's sole marketed drug used to treat Cushing's syndrome, a condition that is primarily cured with mifepristone. ◉ The Economic Impact of Korlym The primary source of revenue for Corcept emanates from the sales of Korlym. The drug has showcased remarkable growth, evidenced by a 39.1% year-over-year sales increase, culminating in $310.6 million during the first half of 2024. This growth is attributed to robust demand and an unprecedented number of patients being prescribed the medication. ◉ Corcept's Stock Growth Factors ● Potential of Relacorilant: Positive GRACE study results suggest relacorilant could be a valuable treatment for Cushing's syndrome, potentially driving revenue growth. ● Pipeline Diversification: Corcept's ongoing exploration of relacorilant in GRADIENT study demonstrates commitment to expanding pipeline. ● Regulatory Progress: Successful completion of GRACE study positions Corcept for a new drug application in late 2024. ● Market Need: Successful relacorilant could fill significant unmet medical need for Cushing's syndrome. Investent Advice by Naranj Capital Buy Corcept Therapeutics NASDAQ:CORT ● Buy Range- 38 - 40 ● Target- 55 - 58 ● Potential Return- 35% - 40% ● Invest Duration- 12-14 Months ◉ Market Capitalization - $4.42 B ◉ Peer Companies ● Prestige Consumer Healthcare NYSE:PBH - $3.644 B ● Jazz Pharmaceuticals NASDAQ:JAZZ - $6.766 B ● Amphastar Pharmaceuticals NASDAQ:AMPH - $2.423 B ● Organon NYSE:OGN - $5.142 B ◉ Relative Strength ➖ The chart distinctly demonstrates that NASDAQ:CORT has significantly surpassed the US Smallcap 2000 index, attaining an impressive annual return of 30%, marking a remarkable accomplishment. ◉ Technical Aspects ● Monthly Chart ➖ The historical chart shows that the stock price is trending upward, marked by a sequence of higher highs and higher lows. ➖ Having recently moved out of the parallel channel, the price is set for additional gains. ● Daily Chart ➖ After an extended period of consolidation, the stock price has formed an Inverted Head & Shoulders pattern. ➖ Post-breakout, the stock has stabilized above the breakout point and is now striving for new highs. ➖ A surge in trading volume suggests that buyers are currently showing significant interest. ◉ Revenue & Profit Analysis ● Year-on-year ➖ In the fiscal year 2023, revenue experienced a significant increase of 20.4%, amounting to $482.4 million, compared to $401.9 million in fiscal year 2022. ➖ However, EBITDA faced a downturn, decreasing to $108.3 million in FY23 from $113.9 million in FY22. ➖ The EBITDA margin also saw a reduction, falling to 22.46% from 28.34% in FY22. ➖ Moreover, diluted earnings per share (EPS) rose by 8% year-over-year, climbing to $0.94 in FY23, up from $0.87 in FY22. **While the growth in EBITDA might raise some concerns, it's crucial to acknowledge that the company is heavily investing in its research and development sector, and this investment has seen substantial increases over the years. ● Quarter-on-quarter ➖ In the most recent June quarter, the company reached an impressive achievement, with quarterly sales hitting a record high of $163.8 million. This represents a 12% increase from the $146.8 million reported in the March quarter and a substantial 39% growth compared to $117.7 million in the corresponding quarter of the previous year. ➖ Additionally, EBITDA rose from $29.6 million to $36.2 million during the latest quarter. ◉ Valuation ◉ PE Ratio ● PE vs Median PE ➖ Corcept Therapeutics sustained a median price-to-earnings ratio of 19.7x from December 2019 to 2023. ➖ Presently, with a price-to-earnings ratio of 35.3x, the stock seems to be relatively expensive. ● PE vs. Peers PE ➖ CORT's Price-To-Earnings Ratio stands at 35.3x, making it quite pricey when compared to the average of its peers, which is only 13.6x. ● PE vs. Industry PE ➖ CORT's valuation seems high, as it has a Price-To-Earnings Ratio of 35.3x, which is considerably above the US Pharmaceuticals industry average of 19x. ◉ PB Ratio ● PB vs. Peers PB ➖ The current price-to-book (P/B) ratio suggests that the stock is slightly undervalued, sitting at 7.4x compared to the peer average of 10.8x. ➖ However, it's important to note that a P/B ratio of 7.4x is typically seen as significantly overvalued. ● PB vs. Industry PB ➖ When we analyze the P/B ratio against the industry standard, CORT stands out as being notably overvalued, with its P/B ratio of 7.4x far exceeding the industry average of just 1.7x. ● PEG Ratio ➖ The stock currently seems to present a compelling investment opportunity, featuring a PEG ratio of 0.84. ◉ Cash Flow Analysis ➖ In FY23, operating cash flow increased to $127 million, compared to $120.3 million in FY22. However, it's essential to recognize that when examining the overall trend from FY19 to FY23, there has been a decline in cash flow from operations. ◉ Debt Analysis ➖ CORT operates without any debt, showcasing the robust financial health of the company. ◉ Top Shareholders ➖ Blackrock presently possesses a significant 15.8% ownership in this stock, while The Vanguard Group maintains approximately 9.1% stakes. ◉ Conclusion Following a comprehensive examination of technical and fundamental metrics, our assessment indicates that Corcept Therapeutics possesses substantial growth potential within the US biotechnology sector. Notwithstanding elevated valuations, the company's increasing research and development expenditures demonstrate a strong commitment to its future prospects. Consequently, we consider Corcept Therapeutics a prudent investment choice at this juncture.
NASDAQ:CORTLong
by NaranjCapital
Tesla (TSLA) Resistance Breakout and Next Target Current Resistance Level: Tesla’s stock (TSLA) is currently testing a key resistance level. Breakout Scenario: If TSLA breaks above this resistance, it could indicate a bullish breakout, suggesting more upside potential. Next Resistance Target: Once the breakout is confirmed, the price could aim for the next resistance level as the target. Confirmation: Wait for Tesla to close above the resistance with strong buying volume. Look for bullish candlestick patterns to confirm the breakout. Risk Management: Place a stop-loss just below the new support level (the previous resistance) to manage the risk of a false breakout or price reversal.
NASDAQ:TSLALong
by rebenga93